https://www.selleckchem.com/products/kpt-185.html
TP53 mutation, one of the most frequent mutations in early-stage lung adenocarcinoma (LUAD), triggers a series of alterations in the immune landscape, progression, and clinical outcome of early-stage LUAD. Our study was designed to unravel the effects of TP53 mutation on the immunophenotype of early-stage LUAD and formulate a TP53-associated immune prognostic model (IPM) that can estimate prognosis in early-stage LUAD patients. Immune-associated differentially expressed genes (DEGs) between TP53 mutated (TP53 ) and TP53 wild-type (TP53